Channel
Legend, Janssen Will Invest $150M to Expand Carvykti Manufacturing in Europe
The firms expect that by expanding manufacturing capacity they can double the sales volume of Carvykti from 10,000 doses in 2025 to 20,000 doses in 2027.
BMS's Breyanzi Gains European Approval as Third-Line Treatment for Follicular Lymphoma
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
RedHill Biopharma to Launch Phase II Trial of Crohn's Disease Drug in Biomarker-Defined Population
The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.
In Brief This Week: Count Me In, TeleRare Health, VolitionRx, Ascentage, Atsena, ClearNote Health
News items for the week of March 10, 2025.
The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeating the disease.
Mar 12, 2025
Mar 11, 2025